Monday, April 08, 2024



Popular Paper on Ivermectin and COVID-19 Contains False Information

Meta analyses are very open to abuse.. I reported recently on another dubious meta-analysis of Ivermectin use. See:
A popular study that claims ivermectin has shown no effectiveness against all-cause mortality contains false information but remains uncorrected.

The meta-analysis, published in 2021 by the journal Clinical Infectious Diseases, explores how groups in randomized, controlled trials fared after receiving ivermectin compared to control groups.

Among five trials included for the portion on all-cause mortality, none showed an effect for ivermectin, the authors claimed.

Ivermectin “did not reduce all-cause mortality,” they wrote.

But the claim is wrong. One of the five trials was described as finding ivermectin recipients were more likely to die, but actually found that ivermectin recipients were less likely to die. “The risk base estimation ... confirmed that the average mortality obtained in all of ivermectin treated arms was 3.3%, while it was about 18.3% in standard care and placebo arms,” the authors of that paper said.

Dr. Adrian Hernandez, an associate professor at the University of Connecticut’s School of Pharmacy, and other authors of the meta-analysis are aware of the false information. The group released their study as a preprint before the journal published it. The first version included the false information. A corrected version properly portrayed the trial’s results for all-cause mortality in a figure summarizing the results, but still falsely said none of the trials showed a benefit against all-cause mortality.

Dr. Hernandez and Clinical Infectious Diseases did not respond to requests for comment.

The lingering false information is in a paper that has attracted numerous citations in other studies, in the press, and on social media. Altmetric, which tracks engagement, scores it at 5,900. A score of 20 or means a paper is doing “far better than most of its contemporaries,” according to the company.

Morimasa Yagisawa of Kitasato University and other researchers pointed out the issue in a March review of ivermectin trials, saying they were “concerned about the spread of misinformation and/or disinformation” about trial results.

“The articles on systematic reviews and meta-analyses are often erroneous or misleading. This is perhaps because the authors were not involved in the clinical trials or patient care and only searched for and analyzed articles and databases on clinical trial results,” they wrote. The problems are “particularly serious” in the paper for which Dr. Hernandez was the corresponding author, the researchers said.

“Although it was a clear error, the wrong content of the preprint was published as a major article in Clinical Infectious Diseases, the official journal of the Infectious Diseases Society of America, without being changed,” they wrote. “Many comments were made questioning the insight of the reviewers and the Editor-in-Chief for publishing a paper with such inconsistencies, but the paper is still published without correction. Since this is a prestigious journal of a prestigious society, an early corrective action is required.”

“There have been several fraudulent meta-analyses, and this is a striking one,” Dr. Pierre Kory, president and chief officer of the FLCCC Alliance and author of the book The War on Ivermectin, told The Epoch Times in an email.

“In this meta-analysis, they selected only 10 of the 81 controlled trials, 33 of which were randomized, on ivermectin that were available at the time. Eight of the ten they selected involved mild COVID-19. Typically, mild COVID does not lead to death. And here they were looking at death rates and, as expected, saw very few. The inclusion criteria they used were intended to show no effect. And they succeeded. Conflicted researchers have been doing this to hydroxychloroquine and ivermectin since the beginning of the pandemic,” he added.

Issues in other meta-analyses include the improper inclusion of papers that did not describe clinical trial results, Mr. Yagisawa and his co-authors said.

They noted that a number of trials have found ivermectin recipients were better off. That includes trials cited by the U.S. Food and Drug Administration (FDA) in its position that ivermectin is not effective against COVID-19.

The FDA recently settled a lawsuit over that position, agreeing to take down several web pages and social media posts.

************************************************

Jacinda Ardern’s zero Covid madness has finally come home to roost

When The Guardian goes into rhetorical overdrive, we can be confident the person, party or policy railed against will finish on the right side of history.

In March 2020, The Guardian lectured Swedish Prime Minister Stefan Lofven on his “Russian roulette-style” Covid-19 strategy. It reported “leading experts” were critical of Lofven for prioritising economic activity over public health. The country’s Covid death toll had reached the alarming total of 25. “How many lives are they prepared to sacrifice so as not to risk a greater impact on the economy?” asked epidemiologist Joacim Rocklov.

By contrast, The Guardian and other pro-lockdown news outlets were fulsome in their praise of Jacinda Ardern and her plan to eliminate the virus in New Zealand. Ardern had responded “with clarity and compassion”, The Guardian gushed back in April 2020.

“New Zealand isn’t just flattening the curve. It’s squashing it,” wrote Washington Post correspondent Anna Fifield.

Fifield had just been to South Korea, where she was “shocked” that airport officials had failed to take her temperature. “I was told simply to self-isolate for 14 days,” she said.

Ardern’s announcement in June 2020 that the virus had been eliminated in New Zealand proved to be somewhat premature. The curve wasn’t flattened. That was delayed until March 2022, when the country eventually crawled out from under the bed.

The chart measuring Covid cases in New Zealand from April 2022 mirrors the chart for Sweden two years earlier: a steep rise to around 2.5 million cases within the first six months, at which point it begins to flatten. New Zealand’s official tally of Covid deaths per million is 1163, 40 per cent higher than it is among the thermometer-dodging South Koreans. It is higher than every state in Australia, except Victoria. It is three times higher than Singapore and 40 per cent higher than the global average.

In October 2021, Ardern told New Zealanders “there is clear evidence the virus finds it harder to spread in vaccinated environments”. Yet in New Zealand, as in Australia, all but a handful of deaths occurred after the rollout of the vaccines, which suggests, at the very least, they were not all they were cracked up to be.

The health benefits of lockdowns were marginal at best. The costs to our social fabric and wellbeing were incalculable.

Among the hundreds of submissions to the federal government’s Covid inquiry released last week are gruelling personal testimonies that speak to the human cost: Australians trapped in India and banned from returning home; forced imprisonment in mediocre hotel rooms upon return; increases in mental illness and family violence, and; unvaccinated Australians treated as lepers.

Human Rights Commissioner Lorraine Finley concludes that Australians endured “some of the most significant restrictions of our human rights ever imposed during peacetime”.

The Commission received 2662 complaints, the biggest response to a single issue since it was established.

It would be nice to put this horrible period behind us and move on. Yet the fiscal burden of Covid will be on our shoulders for some time. Somewhere along the line, we have forgotten that closing borders and social distancing are inherently expensive. Businesses and individuals must be compensated, and even the most ridiculous regulations must be enforced.

So it is hardly surprising government spending in Australia and New Zealand was among the highest in the world. Australian governments, both state and federal, spent the equivalent of 18.2 per cent of GDP to fight Covid, according to data compiled by the International Monetary Fund.

New Zealand was second in the Covid spending rankings at 19.3 per cent of GDP. The US was in first place at 25 per cent of GDP. By contrast, South Korea spent 6.4 per cent of its GDP on pandemic management, and Sweden spent just 4.2 per cent. It would be unfair to criticise Ardern based on hindsight. Like Scott Morrison, she was not to know the path the pandemic would take, nor that attempts to flatten the curve would eventually be futile.

It seemed reasonable to use their countries’ advantages of distance, secure borders and expertise in quarantine procedures to keep the virus out. Equally, however, we must now be honest enough to acknowledge that our governments made the wrong call, unless we are determined to make the same mistakes next time around.

The New Zealand economy will be burdened with the long fiscal tail of the 2020-2022 pandemic for years, if not decades, to come. Australia’s strong economic recovery has masked the fiscal cost of Covid. It vindicates the Morrison government’s decision to direct spending to temporary programs to keep people in jobs and businesses trading rather than bake in permanent welfare spending.

In part, it stems from the good fortune of a resource-driven economy. New Zealand, however, is in a world of pain. Its debt-to-GDP ratio has risen from 27 per cent in 2019 to 37 per cent today. The cost of servicing debt is a significant budget item.

Worse still, it has the second-highest structural deficit in the world, according to the World Bank’s data. The gap between what the government is committed to spend and the revenue it can raise has considerably widened.

The country’s new Prime Minster, Christopher Luxon, has made strong progress in unwinding Ardern’s woke legacy, as the leader of a three-party coalition between the Nationals, Winston Peters’ New Zealand First and David Seymour’s ACT party.

He has reversed the Maorification program, insisting English should remain the country’s first language, begun refocusing the curriculum and banned smartphones from schools, repealed Ardern’s ute tax, scrapped the prisoner reduction target and introduced legislation to crack down on crime gangs.

But the fiscal burden remains his biggest challenge. Fixing it will need far deeper cuts to public spending than Luxon has so far countenanced. Not fixing it will place a drag on the New Zealand economy for years.

Meanwhile, lockdown-phobic Sweden’s economy isn’t exactly roaring, but it’s doing OK by European standards. Sweden’s Covid death toll is on par with or even lower than that in comparable European countries that pursued a lockdown strategy.

In 2019, its debt-to-GDP ratio was eight points higher than New Zealand’s, at 35.6 per cent. Now, it’s five points lower at around 32 per cent. Making trade-offs between health and economic goals turned out to be not such a wicked thing after all.

*************************************************

Also see my other blogs. Main ones below:

http://edwatch.blogspot.com (EDUCATION WATCH)

http://antigreen.blogspot.com (GREENIE WATCH)

http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)

http://australian-politics.blogspot.com (AUSTRALIAN POLITICS)

http://snorphty.blogspot.com (TONGUE-TIED)

https://immigwatch.blogspot.com (IMMIGRATION WATCH)

https://awesternheart.blogspot.com (THE PSYCHOLOGIST)

http://jonjayray.com/blogall.html More blogs

*********************************************************

No comments: